The clinical biostatistics team has strong connection with the Biometry department (Head A. Savignoni), the early phase clinical trial and precision medicine unit where patients are treated with drugs in development (Head C. Le Tourneau), the translational research department in particular the Circulating Tumor Biomarkers laboratory (Charlotte Proudhon), and of course the other teams of the U900. This team is a natural hub between the Curie comprehensive cancer center and Curie Research Center.
A major challenge in oncology drug development remains the identification of predictive biomarkers of efficacy, especially for targeted agents and immuno-therapeutic agents. The increased knowledge of cancer biology has led to the identification of cancer molecular alterations that participate in cancer proliferation, metastases or angiogenesis. This has led to the development of targeted therapies that specifically modulate these molecular alterations or their pathways with an ultimate aim of avoiding giving ineffective and potentially toxic drugs to patients who will not benefit from them. Such a predictive biomarker is a single trait or signature of traits that separates a population of patient with respect to the outcome of interest in response to a particular targeted treatment. Furthermore, quantifying long-term benefit of treatment assignment strategy is a central aspect for decision making and for guiding potential reimbursement of predictive genomic tests.
The main objective of the team will be devoted to the development of statistical methodology for the validation of predictive biomarkers, a brick that play a major role in the precision medicine.